Muscle / Performance · Research guide

IGF-1 LR3 peptide: Muscle / Performance research guide

Q: What is IGF-1 LR3 in plain language?

IGF-1 LR3 is a research peptide we catalogue under “Muscle / Performance.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.

Q: Does this page give medical advice or dosing instructions for IGF-1 LR3?

No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.

Q: Where can I see purity, variants, and pricing for IGF-1 LR3?

Use the “View product” button to open the canonical shop listing for IGF-1 LR3, where specifications and research SKU details are shown.

Q: What about online case reports, before-and-after stories, or forum “logs” for IGF-1 LR3?

Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.

Catalogue reference · Laboratory research only

Not medical advice. IGF-1 LR3 is sold for research. This guide does not recommend dosing, diagnosis, or therapy.

IGF-1 LR3 is investigated for IGF-receptor signalling, muscle cell culture work, and growth-factor cascades downstream of GH.

Plain-language snapshot

One-paragraph overview from our research datasheet—still scientific, but faster to read than the full mechanism list below.

IGF-1 LR3 — 83-amino acid extended IGF-1 analogue with Arg3 substitution eliminating IGFBP binding for 3-fold enhanced potency and 20–30 hour half-life.

What shows up in scientific writing (general background)

Many readers want context before diving into pathways. The list below summarises what researchers and reviewers discuss—cells, animals, and (for some drug-class molecules) formal clinical trials. It is not a promise of results for any individual.

“Reported” means described in the literature, not recommended for personal use. Our peptides are for laboratory research only.

Typical study contexts & reported directions

Cell-culture papers use LR3 variants to maintain IGF receptor stimulation across longer incubations—an assay convenience, not a human protocol.
Animal work may examine muscle regeneration models; results are species- and model-specific.
Muscle injury, overload, or culture models examining growth-factor cascades and repair timelines.
IGF/IGFBP biology in cell lines and animals where the question is signalling, not “gains” in people.
Peer-reviewed preclinical work sometimes describes experiments that track whether arg3 substitution eliminates IGFBP binding increasing free bioavailable IGF-1 approximately 3-fold
Peer-reviewed preclinical work sometimes describes experiments that track whether 13-amino acid N-terminal extension enhances metabolic stability extending half-life to 20–30 hours
Peer-reviewed preclinical work sometimes describes experiments that track whether full IGF-1R agonist activating PI3K/Akt/mTOR protein synthesis and RAS/RAF/MEK/ERK proliferation pathways
Peer-reviewed preclinical work sometimes describes experiments that track whether bypasses hepatic GH/JAK2/STAT5 axis — direct peripheral tissue receptor activation

Why Muscle / Performance research discusses this compound

Here the literature centres on muscle repair, growth-factor signalling, and how tissues respond after overload or injury in preclinical work.

Quick takeaways

Long half-life variants are tools in cell biology rather than “recovery shortcuts” in humans.

Themes from preclinical literature (technical)

Below are mechanistic bullet points as they appear in our product reference material -useful for researchers comparing pathways. They are not simplified health claims.

Arg3 substitution eliminates IGFBP binding increasing free bioavailable IGF-1 approximately 3-fold
13-amino acid N-terminal extension enhances metabolic stability extending half-life to 20–30 hours
Full IGF-1R agonist activating PI3K/Akt/mTOR protein synthesis and RAS/RAF/MEK/ERK proliferation pathways
Bypasses hepatic GH/JAK2/STAT5 axis — direct peripheral tissue receptor activation
Promotes hyperplasia (new muscle cell formation) and mitogenesis via satellite cell activation
Counteracts myostatin signaling through MyoD pathway activation in Duchenne muscular dystrophy models

Typical handling notes (from our datasheet)

Storage: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. ~5% degradation per year refrigerated. - see our storage guide for best practices on temperature, light, and shelf life.

Typical research dosing discussion (literature-style): 20–100 mcg subcutaneously or intramuscularly · Once daily, typically post-training or divided bilateral injections · t½ ≈ 20–30 h (vs. 12–15 h for native IGF-1); enhanced bioavailability due to <2% IGFBP binding (vs. ~98% for native IGF-1); produced via recombinant E. coli expression with chromatographic purification and refolding. Not FDA-approved — mecasermin (native rhIGF-1) is approved for pediatric primary IGFD. Banned by WADA.

For preparation, follow the step-by-step reconstitution guide and use the reconstitution calculator to confirm draw volumes. Review subcutaneous injection basics for technique, and always verify batch purity by reading the COA.

Frequently asked questions

What is IGF-1 LR3 in plain language?
IGF-1 LR3 is a research peptide we catalogue under “Muscle / Performance.” This article explains how scientists discuss it in published literature and what study types usually appear—not as a consumer product claim.

Does this page give medical advice or dosing instructions for IGF-1 LR3?
No. Content is for laboratory and research literacy only. It does not diagnose, treat, or prevent disease, and is not a dosing guide.

Where can I see purity, variants, and pricing for IGF-1 LR3?
Use the “View product” button to open the canonical shop listing for IGF-1 LR3, where specifications and research SKU details are shown.

What about online case reports, before-and-after stories, or forum “logs” for IGF-1 LR3?
Those sources are not peer-reviewed evidence. This guide focuses on preclinical literature and, where relevant, formal clinical trial programmes for drug-class molecules. Anecdotes may be interesting culturally; they are not a safe basis for dosing or medical decisions.

Need vial specs & pricing?

Open the shop listing for variants, purity notes, and research SKU details.

View product

Also known as: Long R3 IGF-1, Long Arginine 3 IGF-1, IGF-1 LR3, LR3-IGF-1, Insulin-Like Growth Factor 1 Long R3, LONG R3 IGF-I, Recombinant Long R3 IGF-1